A customised convolutional neural network detected mitotic figures in breast cancer histopathology images with a reported ...

Cancer vaccines are having a moment. Late last week, the drug makers Merck and Cambridge-based Moderna announced that ...

A laboratory study reports that the AMPK activator AICAR selectively arrests esophageal squamous cell carcinoma cells in S ...

A surprise diagnosis inspired a health writer to investigate what went wrong—and what is in our control to stave off this ...

Key Advances in Head and Neck, Thyroid, and Skin Cancers / Aurora Mirabile, cancer, esmo 2026, ESMO Congress 2026, head and ...

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used ...

BreakBio, a biotechnology company developing personalized cancer immunotherapies, has appointed Dr. Stephen M. Hahn, former ...

The academic whose removal from Adelaide Writers’ Week triggered a mass boycott by authors and the eventual cancellation of ...

Samsung Bioepis presented Phase 1 results for SB27, its biosimilar candidate to Keytruda, at the European Society for Medical Oncology (ESMO 2026).

Discover how lab-grown organoids are advancing disease research, drug testing and precision medicine, and why they cannot yet ...

A Samsung Bioepis representative presents a poster on the Phase 1 results for the Keytruda biosimilar candidate SB27 at the European Society for Medical Oncology (ESMO) congress in Madrid, Spain, on ...

SOUTH SAN FRANCISCO, Calif, Oct. 26, 2026 (GLOBE NEWSWIRE) -- , (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed ...